Alembic Focuses On Complex, High Value Drugs

Alembic Pharmaceuticals reported a Q2FY26 performance with revenue rising 16% year-on-year to ₹1,910 crore and PAT up 20% to ₹185 crore. EBITDA increased 26% to ₹325 crore, with margins at 17%. Growth was supported by the India branded business (₹639 crore), the expanding US generics portfolio, and steady Ex-US and API operations. The company launched five new products globally and received six ANDA approvals during the quarter, indicating its focus on innovation, operational efficiency, and portfolio diversification.